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BY-NC-ND license (http://creativecomBackground/purpose: The Taiwanese FRAX calculator was launched in 2010. However, cost-
effectiveness thresholds for the prescription of antiosteoporosis medications were not estab-
lished. This study aims to establish and evaluate FRAX-based probability thresholds in Taiwan.
Methods: Using previous data from Taiwan and literature, we determined cost-effectiveness
thresholds for prevention of osteoporotic fractures by alendronate with a Markov model, as
well as using two other translational approaches. Sensitivity analysis was applied using
different alendronate prices. A clinical sample was used to test these Taiwan-specific thresh-
olds by determining the percentages of high-risk patients who would be qualified for current
National Health Insurance reimbursement.
Results: With the Markov model, the intervention threshold for hip fracture was 7% for women
and 6% for men; for major osteoporotic fracture, it was 15% for women and 12.5% for men.
Both translational approach models were cost effective only for certain age groups. However,
if branded alendronate was reimbursed at 60% of the current price, they became cost effective
in almost all age groups. This clinical screening study showed that the National Health Insur-
ance Administration model identified the highest proportion (44%) of patients qualified for Na-
tional Health Insurance reimbursements, followed by the Markov model (30%), and the United
States model (22%).ave no conflicts of interest relevant to this article.
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optimize treatment strategies. The government is encouraged to incorporate FRAX-based ap-
proaches into the reimbursement policy for antiosteoporosis medicines.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
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nc-nd/4.0/).(2) To test Taiwan-specific FRAX cutoff points in clinicalIntroduction
The National Nutrition and Health Survey in Taiwan reported
that 41.2% of women and 22.6% of men over 50 years of age
have osteoporosis, based on the bone mineral density (BMD)
data.1 The hip fracture (HF) incidence in Taiwan was among
the highest in the world.2 However, a study showed that only
25% of female HF sufferers in Taiwan underwent a BMD test,
33% received antiosteoporosis medications (AOMs), and 60%
had a diagnosis of osteoporosis.3
To reduce the osteoporosis care gap, efforts were made
to improve awareness among patients and healthcare pro-
viders, including making osteoporosis a national priority,4
publishing the Taiwan Osteoporosis Practice guideline5
with nationwide educational courses for six types of
healthcare professionals,4 training courses for osteoporosis
nursing specialists,6 a nationwide osteoporosis education
and screening program covering approximately 5000
adults,7 press conferences on osteoporosis issues, etc.
In Taiwan, a gap exists between comprehensive osteo-
porosis care and the current payment standards from Na-
tional Health Insurance Administration (NHIA) on BMD tests
and AOMs. To be reimbursed for dual-energy X-ray absorp-
tiometry, patients must have a fragility fracture or be a
woman receiving AOMs. NHI does not reimburse strontium
ranelate, and teriparatide is considered a second-line
agent. For all other AOMs, reimbursement is granted if
the patient experiences a fragility fracture of the hip or
spine area and has a BMD T-score of 2.5, or experiences
at least two fragility fractures of the hip or spine area and
has a BMD T-score of <1.8 The rules are stricter than those
suggested by domestic or international professional soci-
eties,5,9,10 which emphasize treating patients with fragility
fractures independent of BMD and considering the incor-
poration of algorithms based on the World Health Organi-
zation FRAX fracture risk assessment tool.
The current NHI payment standards for AOMs were not
based on cost-effectiveness analysis. Even though the
Taiwanese FRAX calculator was launched in 2010,5,11 cost-
effectiveness probability thresholds, against which AOM
treatment has to be assessed, have not been established.
The Taiwan Osteoporosis Practice guideline suggested
adopting United States of America thresholds [3% for HF, and
20% for major osteoporotic fracture (MOF)], drawing on
expert advice.5 Empirical data showed that the 3% HF cutoff
point may be very low in Taiwan, because nearly 90% of older
adults (65 years) were screened as being at high risk in one
cohort, compared with 33% using the 20% MOF cutoff point.12
The objective of this study is therefore two-fold:
(1) To establish practical Taiwanese FRAX-based inter-
vention thresholds in Taiwan using the Markov model
and translational approachhan D-C, et al., Establishing and
, http://dx.doi.org/10.1016/j.jfmsamples and determine the optimal one, which can
identify more high-risk patients for medication
reimbursementMaterials and methods
The Markov model used epidemiological, cost, and quality
of life data to estimate the fracture probability at which
alendronate treatment became cost effective compared
with no treatment. Two translational approach models
were developed based on prior guidelines.5,9,10 The “frac-
ture model” adopted the assumption that individuals with a
fracture probability equal to or greater than that of pa-
tients with a prior fragility fracture should be considered
for treatment. From the Taiwanese NHI AOM payment
standards, we developed the “NHIA model” assuming that
patients with a fracture probability equal to or greater than
that of patients with a prior fragility fracture and BMD
T-score Z 2.5 should be treated.8
Markov model approach
We constructed a Markov model to estimate the cost-
effective MOF and HF intervention thresholds.13 There are
four health states in the model: well, fracture, post-
fracture, and death. The cycle was set at 1 year and every
patient was followed through the model until death.14
When the parameters in the model were not available
from Taiwan data, we applied estimates from other coun-
tries, indexing the data source, a method applied in a
previous European osteoporosis burden report.15
HF Markov model
We used a mathematical formula to derive the 1-year
probability of HF from the 10-year probabilities estimated
from the Taiwanese FRAX calculator. This number would
vary in many simulations until cost-effectiveness cut points
were found. All other parameters in Table 1 were obtained
from Taiwan data,5,16 except that transition probability
from postfracture to death was derived from a Korean
study.17
MOF Markov model
Fracture incidences were obtained from the Malmo study,18
and the 2010 Taiwan population figures were used to esti-
mate the proportion of each component of MOF (vertebra,
hip, humerus, and forearm) in Taiwan. Taiwanese NHI data
were used for calculating the probability of refracture.19
However, the probability of transition from “fracture” to
“death” was estimated from a US study.20 As there were noevaluating FRAX probability thresholds in Taiwan, Journal of the
a.2016.03.006
Table 1 Transition probabilities and input value for interventions in osteoporosis (hip fracture model).
From To Transition probabilities Utility
Well (A) Fracture (B) Postfracture (C ) Death (D)(Y) (/)
Well (A) 1 e B e D 0.0072 d 0.0063 1
Fracture (B) d 0.0250 1 e B e D 0.1500(F)/0.2200(M) 0.66
Postfracture (C ) d d 1 e D 0.0700 0.8
Death (D) d d d 1 0
All parameters were used in accordance with the literature; sex-specific parameters are indicated as follows: F Z female; M Z male.
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+ MODELdata on the transition from “postfracture” to “death,” we
assumed that these probabilities were 33% of those from
fracture to death, based on group consensus (Table 2).
Utility value of HF
We used a formula to convert the Taiwanese HF Short-Form
Health Survey (SF-36) scores21 to EuroQoL group EQ-5D
utility scores and calculated the utility of HF status as
0.66.22 Utility of subsequent years after HF was estimated
to be 0.8, based on a systematic review (Table 1).23
Utilities of MOF
Based on the utility data from previous studies,23,24 and the
proportion of each fracture type estimated earlier, we
calculated the utility of different statuses (Table 3).
Efficacy of treatment
The efficacy of alendronate, after 5 years of use, in
reducing fracture risk was derived from a systematic review
as 0.62 (0.40e0.96).25
Cost assumptions
The cost was based on 2010 values, converted into US
dollars (USD). Both effect and cost were discounted at an
annual rate of 1.36%. The currency exchange rate between
USD and new Taiwan dollar was set at 1:30.
Hip fracture
From a Taiwanese retrospective study, the cost of hospi-
talization following HF, including inpatient rehabilitation,
was estimated to be $3243/year.14 Our orthopedic wardTable 2 Transition probabilities and input values for interventi
From To Transition pr
Well (A) Fracture (B) P(Y) (/)
Well (A) 1 e B e D 0.0152(F)/0.0127(M) d
Fracture (B) d 0.0515 1
Postfracture (C ) d d 1
Death (D) d d d
All parameters were used in accordance with the literature; sex-spec
Please cite this article in press as: Chan D-C, et al., Establishing and
Formosan Medical Association (2016), http://dx.doi.org/10.1016/j.jfmdata showed that nearly 25% of HF patients needed long-
term care (LTC) after hospital discharge. Specifically, 11%
were transferred to nursing homes (cost $1760/month), 13%
of them lived at home with care provided by foreign-paid
caregivers ($480/month), and 2% of them lived at home
with domestic-paid care givers ($1242/month). The average
annual outpatient costs (clinic visits and outpatient reha-
bilitation) of HF were $173, according to 2010 NHI
statistics.
Major osteoporotic fracture
From an NHI database study, the cost of hospitalization for
MOF were estimated to be $1533.26 We assumed that only
patients suffering from HF would require LTC. The annual
cost of LTC for men and women after LTC was obtained
from the proportion of each type of fracture in Table 3 and
LTC costs for HF. The average annual outpatient costs for
men and women were estimated to be $214 and $200,
respectively, from NHI statistics.
Treatment with branded alendronate cost USD 450/year.
The cost of BMD measurement by dual-energy X-ray ab-
sorptiometry at two sites was USD 40/year.Willingness to pay
We set the willingness to pay thresholds for each additional
Quality Adjusted Life Year (QALY) gained as twice the
Taiwan gross domestic product, which was USD 42,628 in
2010.
Translational approach
To derive the intervention threshold from the two trans-
lational models, we fixed the body mass index as 25 kg/m2
for men and 23 kg/m2 for women. The 10-year probability
of MOF and HF at 5-year intervals was derived from the
Taiwan FRAX calculators5 and plotted as figures. In theon in osteoporosis (major osteoporotic fracture model).
obabilities Utility
ostfracture (C ) Death (D)
0.0063 1
e B e D 0.0780(F)/0.1130(M) 0.75(F)/0.7(M)
e D 0.0260(F)/0.0380(M) 0.91(F)/0.93(M)
1 0
ific parameters are indicated as follows: F Z female; M Z male.
evaluating FRAX probability thresholds in Taiwan, Journal of the
a.2016.03.006
T
a
b
le
3
A
ge
-s
p
e
ci
fi
c
e
st
im
a
te
d
n
u
m
b
e
r
o
f
th
e
m
a
jo
r
o
st
e
o
p
o
ro
ti
c
fr
a
ct
u
re
s
a
t
d
if
fe
re
n
t
si
te
s
in
m
a
le
a
n
d
fe
m
a
le
.
T
yp
e
o
f
fr
a
ct
u
re
s
A
ge
(y
)
T
o
ta
l
(N
,
%
)
U
ti
li
ty
(f
ra
ct
u
re
)
F
ra
ct
u
re
a
U
ti
li
ty
(p
o
st
fr
a
ct
u
re
)
P
o
st
fr
a
ct
u
re
b
50
e
54
55
e
59
60
e
64
65
e
69
70
e
74
75
e
79
80
e
84
85
e
89
M
a
le
V
e
rt
e
b
ra
17
23
92
1
11
32
85
1
14
91
14
52
17
59
10
15
10
,3
43
37
0.
59
0.
22
0.
93
0.
34
P
ro
xi
m
a
l
h
u
m
e
ru
s
57
4
24
0
30
0
32
3
61
8
42
0
44
3
42
9
33
49
12
0.
65
0.
08
1
0.
12
H
ip
76
9
65
8
35
6
71
0
89
0
14
71
28
65
14
37
91
56
33
0.
7
0.
23
0.
8
0.
26
D
is
ta
l
fo
re
a
rm
89
3
11
68
70
1
99
1
26
6
41
1
48
8
11
9
50
37
18
0.
95
6
0.
17
1
0.
18
T
o
ta
l
27
,8
85
10
0
0.
70
0.
91
F
e
m
a
le
V
e
rt
e
b
ra
14
44
12
62
15
95
16
91
27
24
29
17
20
42
14
48
15
,1
25
24
0.
59
0.
14
0.
93
0.
23
P
ro
xi
m
a
l
h
u
m
e
ru
s
11
12
10
15
66
3
13
56
13
44
16
52
10
27
98
9
91
58
15
0.
65
0.
10
1
0.
15
H
ip
54
7
43
9
10
21
11
98
19
33
34
35
37
88
32
65
15
,6
26
25
0.
7
0.
18
0.
8
0.
20
D
is
ta
l
fo
re
a
rm
37
39
36
43
29
91
26
62
31
65
27
10
21
21
12
24
22
,2
56
36
0.
95
6
0.
34
1
0.
36
T
o
ta
l
62
,1
64
1.
00
0.
76
0.
93
a
T
h
e
u
ti
li
ty
va
lu
e
fo
r
m
a
jo
r
o
st
e
o
p
o
ro
ti
c
fr
a
ct
u
re
s
is
ca
lc
u
la
te
d
a
s
p
e
rc
e
n
ta
ge
s
o
f
ty
p
e
o
f
fr
a
ct
u
re
s
m
u
lt
ip
li
e
d
b
y
u
ti
li
ty
fo
r
fr
a
ct
u
re
.
b
T
h
e
u
ti
li
ty
va
lu
e
fo
r
m
a
jo
r
o
st
e
o
p
o
ro
ti
c
fr
a
ct
u
re
s
is
ca
lc
u
la
te
d
a
s
p
e
rc
e
n
ta
ge
s
o
f
ty
p
e
o
f
fr
a
ct
u
re
s
m
u
lt
ip
li
e
d
b
y
u
ti
li
ty
fo
r
p
o
st
fr
ac
tu
re
.
4 D.-C. Chan et al.
+ MODEL
Please cite this article in press as: Chan D-C, et al., Establishing and
Formosan Medical Association (2016), http://dx.doi.org/10.1016/j.jfmfracture model, all patients were assumed to have a prior
fragility fracture while other risk factors were negative,
and BMD data were not available. In the NHIA model, all
patients were assumed to have a prior fragility fracture and
a BMD T-score of 2.5, while other risk factors were
negative.
Sensitivity analysis
Sensitivity analysis was applied to determine whether
different medication costs would affect the cost-effective
intervention thresholds.
Empirical applications of three intervention thresholds
The cutoff points of FRAX, determined by three different
approaches, were used to recruit high-risk patients in
clinics for osteoporosis assessment. This study was
approved by the Board of Ethics of National Taiwan Uni-
versity, Taipei. Groups A, B, and C applied the US threshold,
NHIA model threshold, and Markov model threshold,
respectively. After enrollment, participating physicians
confirmed the presence of hip or spine fractures using
radiological tests, and prescribed BMD measurement ac-
cording to NHI regulations and the Taiwan Osteoporosis
Practice guideline.5Results
Figure 1 shows the Markov model threshold at which
alendronate treatment becomes cost effective. The HF
intervention threshold was 7% for women and 6% for men,
and the threshold for MOF was 15% for women and 12.5% for
men.
Figure 2 shows a plot of the two translational approach
models (fracture model and NHIA model) by sex, age, and
fracture type (HF or MOF). In general, thresholds from the
NHIA model were higher for younger people and lower for
older ones, compared with those derived from the fracture
model. With a price of USD 450, intervention became cost
effective for women aged at least 60 years (NHIA model,
MOF) and at least 65 years (fracture model, MOF). For men,
the interventions were cost effective only between ages
55 years and 85 years (NHIA model, MOF), and between
ages 75 years and 90 years (fracture model, MOF). For HF,
treatment was cost effective for women aged over 65 years
(NHIA model) and between 65 years and 85 years (fracture
model), and for men aged between 55 years and 85 years
(NHIA model) and over 75 years (fracture model).
In the sensitivity analysis, the intervention threshold did
not decrease very much when the cost decreased from USD
450 to 390 (the current generic price in Taiwan). However,
if the cost reduced to 60% of the current price (USD 270),
the intervention threshold decreased to <5% for MOF and to
about 2% for HF. Under these conditions, almost any FRAX-
based age-specific intervention thresholds from the two
translational approaches was considered cost effective (see
Figure 2).
In this clinic screening study, each group enrolled 75
patients. However, only 57 (Group A), 54 (Group B), and 58
(Group C) patients completed radiological tests and BMD
measurements, which were required to determine whether
they were eligible for NHI reimbursements. Overall, 33% ofevaluating FRAX probability thresholds in Taiwan, Journal of the
a.2016.03.006
Figure 1 Ten-year probability of major osteoporotic and hip
fracture by sex. The cost-effectiveness threshold was set at
willingness to pay that is twice the Taiwan gross domestic
product per capita. Cost effectiveness of alendronate was
compared with no treatment as a function of 10-year proba-
bility of hip fracture and major osteoporotic fracture in
Taiwan. The dashed lines show the fracture probabilities (hip
fracture: 6% for men, 7% for women; major osteoporotic
fracture: 12.5% for men, 15% for women) are cost effective in
Taiwan for willingness to pay set at twice the gross domestic
product per capita of Taiwan. ICER Z incremental cost-
effectiveness ratio.
FRAX probability thresholds in Taiwan 5
+ MODELthe participants (NZ 57) qualified for NHI reimbursement,
12% (N Z 20) had fractures with a BMD T-score of >2.5,
15% (NZ 26) did not have fractures but were osteoporotic,
and the rest (39%, NZ 66) did not have fractures and were
not osteoporotic. The thresholds determined by the NHIA
model (Group B) identified the largest percentage of pa-
tients (44%) who were eligible for government-funded
medications (Table 4).Discussion
This study has shown that treatment of osteoporosis can be
delivered with a FRAX-based strategy, which incorporates
sex- and fracture-specific thresholds. Among the three
proposed models, the intervention thresholds derived from
the current NHIA payment standards would detect most
patients eligible for government-reimbursed AOMs. How-
ever, the cost-effectiveness threshold was very sensitive toPlease cite this article in press as: Chan D-C, et al., Establishing and
Formosan Medical Association (2016), http://dx.doi.org/10.1016/j.jfmdrug price changes. If generic alendronate was reimbursed
at 60% of the current price of branded drugs, it would be
cost effective for nearly all age-specific thresholds derived
by both models with a translational approach.
When applying the Markov model using Taiwanese data,
our intervention threshold based on MOF was higher than
that in Spain or Hong Kong,27,28 but lower than that in
Japan,29 Switzerland,30 or the USA.10 Similarly, our inter-
vention threshold for HF is lower than that in France but
higher than the US threshold.10,31 There may be several
reasons for these differences. First, the risk of fracture
varies in different countries and depends on the method-
ology used for epidemiological studies. Second, we
included some indirect costs, including those for post-
fracture care delivered by a nursing home or in the com-
munity. Third, the willingness to pay for healthcare also
varies with the gross domestic product in different
countries.
Several structural issues in the modeling analysis should
be addressed. Length of treatment and adherence to drug
therapy can be important determinants for prevention of
osteoporotic fractures, but are usually omitted from pub-
lished models. Similarly, adverse drug events will cause
discontinuation of drug therapy and may increase the cost.
Osteonecrosis of the jaw, gastrointestinal problems, and
atypical subtrochanteric and diaphyseal femoral fractures
should be considered in future modeling analyses.
Experts in Taiwan previously recommended drug therapy
for those with a 10-year probability of MOF higher than 20%
and HF higher than 3% in Taiwan, adopting from the US
threshold, but no domestic cost-effectiveness analysis and
data were available.5 Our intervention thresholds from the
Markov model were higher for HF but lower for MOF than
the US models. When applying both thresholds to a com-
munity sample of close to 2000 people, our new threshold
identified only about 67% of high-risk individuals who
required referral for further evaluation.32 Previous con-
cerns about the oversensitivity of the 3% cutoff point can be
partially prevented.12 It also highlighted the importance of
developing country-specific FRAX thresholds.
We established age-specific thresholds using a trans-
lational approach. This approach was developed based on
the guideline of the National Osteoporosis Guideline Group
in the UK, with the assumption that individuals who have a
higher probability of fracture than those who already had a
fragility fracture should be eligible for drug therapy.9 It has
also been adopted by Ireland,33 Turkey,34 Switzerland,30
and Belgium.12,35 Besides the National Osteoporosis
Guideline Group fracture model, we also derived a stricter
NHIA model based on our reimbursement rules (previous
fragility fracture and T-scoreZ 2.5). The threshold of the
NHIA model was higher than that of the fracture model for
younger patients. However, it became lower with
increasing age (roughly after the age of 70e80 years). As
older adults tended to have a T-score of <2.5, fixing BMD
at that T-score reduced the risk of future fragility fractures.
In our clinical screening study, patients who were clas-
sified to be at high risk using the NHIA model were most
likely to qualify for government-funded medication, fol-
lowed by the threshold derived from the Markov model and
then the US threshold. In Taiwan, payment standards of
AOMs from the NHI are based only on the history of fragilityevaluating FRAX probability thresholds in Taiwan, Journal of the
a.2016.03.006
Figure 2 Ten-year probability of major osteoporotic and hip fracture by sex, age, and fracture type. Cost-effectiveness method
and translational method are shown. Sex-specific and fracture-type-specific intervention thresholds for alendronate therapy were
used to reduce fractures derived from translation approach. Fracture model: age-dependent risk derived from positive history of
fragility fracture; NHIA model: age-dependent risk derived from a positive history of fragility fracture and the BMD T-score as 2.5.
The dashed lines show the intervention thresholds with four levels of price of alendronate in the sensitivity analysis. BMD Z bone
mineral density; NHIA Z National Health Insurance Administration.
Table 4 Clinical sample screening results from three FRAX-based intervention thresholds.
A B C Total
N (%)
57 33.7% 54 32.0% 58 34.3% 169 100.0%
NHI reimbursable 13 22.8% 24 44.4% 20 34.5% 57 33.7%
fracture (þ) & T > 2.5 5 8.8% 8 14.8% 7 12.1% 20 11.8%
fracture () & T  2.5 11 19.3% 8 14.8% 7 12.1% 26 15.4%
fracture () & T  2.5 28 49.1% 14 25.9% 24 41.4% 66 39.1%
Group A: United States of America intervention thresholds (20% for major osteoporotic fracture and 3% for hip fracture).
Group B: One-part fracture with T-score < 2.5 with translational approach.
Group C: Cost-effectiveness Taiwanese thresholds (major osteoporotic fracture: 12.5% for male and 15% for female; hip fracture: 6% for
male and 7% for female).
NHI Z National Health Insurance.
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However, many rural areas may not have easy access to
BMD assessments, and many fragility fracture cases are
therefore ineligible for funding. The NHIA model-derived
FRAX threshold fitted most closely with the current NHI
reimbursement rules and was also relatively difficult to
reach. If future reimbursement policy incorporates this
model, more high-risk patients can be treated. However,
whether treating such patients can reduce fracture rates
and improve patient outcomes should be examined in
further research.
There are several limitations to our study. First, in the
Markov model, some domestic fracture-related data are
lacking; further research is needed to obtain such data to
provide more accurate estimations. Second, extraskeletal
effects of alendronate treatment, such as adverse drug
events, were not considered in our analysis because their
definite risk and cost were uncertain in Taiwan. Third,
complex interactions between the effectiveness of contin-
uous adherence to medication programs and the impact of
this on cost were not included in the model. Fourth, we
applied a fixed value of body mass index to the transitional
model, but the probability of fracture will also vary with
different body mass indexes. Lastly, new generic medica-
tions and revised payment standards may also influence the
real situations in clinical practice.
The risk of HF in the Taiwanese population is the highest in
the Asia-Pacific region. This FRAX-based analysis has estab-
lished fixed and age-specific intervention thresholds to
improve the performance of FRAX-based screening and clin-
ical managements. Adaption of FRAX-based medication re-
imbursements by NHI may allow treatment for more high-
fracture-riskpatientsand improveosteoporosiscareinTaiwan.Acknowledgments
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